Features

A new stem cell-based test may add certainty to efforts to predict whether so-called variants of uncertain significance will contribute to the development of diseases or be harmless. 

Coronary artery calcium scanning is not a Magic 8 Ball, but it is a powerful predictor and a valuable tool for cardiology practices.

I don’t need to tell you that social determinants of health (SDoH) present challenges for your patients. You’ve seen the data indicating that as much as 80 percent of an individual’s health comes from factors other than the clinical care he or she receives. You know the impact of disparities. 

ACC.19 will feature 36 late-breaking clinical trials and clinical research studies, starting with the Apple Heart Study’s findings on the ability of a smartwatch to help identify atrial fibrillation. That question is just one of many the conference will address, says ACC.19 Program Chair Andrew Kates, MD, professor of medicine and director of the cardiology fellowship program at Washington University School of Medicine in St. Louis. During a conversation with Cardiovascular Business, Kates predicted trial highlights and previewed some ACC.19 program innovations. 

With use of cardiac implantable electronic devices on the rise, experts stress device selection, prophylactic antibiotics, pre-procedural protocols and post-implementation vigilance.

Is Interactive Virtual Reality Poised to Deliver a ‘Eureka Moment’ for Cardiology?

In this magazine’s cover story, we examine the work that still needs to be done to improve women’s heart health. Despite significant progress, too many women aren’t even aware that heart disease is relevant to them, let alone their gender’s leading cause of death.

Ramping up the battle against cardiovascular disease in women represents a golden opportunity to move the needle on mortality.

The moniker is in flux, but patients, clinicians and organizations are embracing the connectedness of virtual hospitals.

For-profit and not-for-profit healthcare facilities may value the health of their cath lab employees differently. Without a clear indication of the bottom-line impact, some hospitals may be forgoing protective equipment and sacrificing the long-term health of their workers. Should the C-suite prioritize worker health when allocating investment dollars? 

Will operators be able to replicate COAPT’s restraint and its outcomes?

Do you remember the anticipation around renal denervation? And then the ACC.14 presentation of the SYMPLICITY HTN-3 results, where the excitement about a new way to treat resistant hypertension seemed to crash?